EMBARC – Bronchiectasis.

Journal Ref: BMJ Clin Evid. 2015 Feb 25;2015. pii: 1507.
Abstract:

Bronchiectasis is usually a complication of previous lower respiratory infection and/or inflammation. It causes chronic cough, copious production of sputum (often purulent), and recurrent infections, and may cause airway obstruction bearing some similarities with that seen in COPD. It may complicate respiratory conditions such as asthma or COPD. It can be associated with primary ciliary dyskinesia, primary immunodeficiencies, certain systemic diseases such as inflammatory bowel disease and rheumatoid arthritis, and foreign body inhalation. Bronchiectasis can be due to cystic fibrosis but this is excluded from this review.

METHODS AND OUTCOMES:

We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments in people with non-cystic fibrosis (non-CF) bronchiectasis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). We performed a GRADE evaluation of the quality of evidence for interventions.

RESULTS:

We found 23 studies that met our inclusion criteria.

CONCLUSIONS:

In this systematic review we present information relating to the effectiveness and safety of the following interventions: airway clearance techniques, corticosteroids (inhaled), exercise or physical training, hyperosmolar agents (inhaled), mucolytics, prolonged-use antibiotics, and surgery.

Contact

EMBARC
Carl-Neuberg-Straße 1, 30625 Hannover, Germany
[email protected]

Opening hours

Mon - Fr 10:00 - 17:00
Sat - 10:00 - 15:00
Sun - 10:00 - 13:00

Produkt zum Warenkorb hinzugefügt.
0 Artikel - 0,00